Abstract
Zidovudine therapy seems to be effective for reducing vertical transmission of HIV infection and preventing paediatric AIDS. Besides those cases in which it is indicated, zidovudine plays an important role in safeguarding maternal well-being. Even though no data indicating teratogenic effect of this drug exist, its use during the first trimester should be limited to those cases where it is absolutely indicated. All undergoing this therapy should be informed that no information regarding the long term effects of this drug are available yet. Further controlled studies are necessary if this drug is to be used in those cases where it could actually be of benefit.
| Original language | English |
|---|---|
| Pages (from-to) | 43-47 |
| Number of pages | 5 |
| Journal | Drugs |
| Volume | 50 |
| Publication status | Published - 1995 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Female
- Guidelines as Topic
- HIV Infections
- Humans
- Infectious Disease Transmission, Vertical
- Maternal-Fetal Exchange
- Pregnancy
- Pregnancy Complications, Infectious
- Zidovudine
Fingerprint
Dive into the research topics of 'Guidelines for the use of zidovudine in pregnant women with HIV infection'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver